NASDAQ:NTLA Intellia Therapeutics (NTLA) Stock Price, News & Analysis $11.91 -0.67 (-5.33%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$12.09 +0.18 (+1.54%) As of 05:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Intellia Therapeutics Stock (NASDAQ:NTLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Intellia Therapeutics alerts:Sign Up Key Stats Today's Range$11.82▼$12.4850-Day Range$10.97▼$13.5152-Week Range$7.95▼$28.25Volume5.18 million shsAverage Volume5.84 million shsMarket Capitalization$1.67 billionP/E RatioN/ADividend YieldN/APrice Target$20.72Consensus RatingHold Company Overview Intellia Therapeutics, Inc. is a biotechnology company focused on developing genome-editing therapies using CRISPR/Cas9 technology. The company is working to create treatments that can directly modify disease-causing genes, including through in vivo approaches in which the editing machinery is delivered into a patient’s body. Its pipeline has included NTLA-2001, an investigational therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational program targeting kallikrein for hereditary angioedema. Intellia has also pursued additional research programs in areas such as genetic liver diseases and other serious conditions. Founded in 2014, Intellia was established by a group of scientists and entrepreneurs, including CRISPR pioneer Jennifer Doudna. The company’s research and clinical-development activities have included collaborations and studies in the United States and other regions. John M. Leonard serves as president and chief executive officer, overseeing Intellia’s development of CRISPR-based medicines.AI Generated. May Contain Errors. Read More Intellia Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreNTLA MarketRank™: 3.315949300235 of 5 starsIntellia Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 276th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingIntellia Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.26, and is based on 1 strong buy rating, 9 buy ratings, 8 hold ratings, and 5 sell ratings.Upside PotentialIntellia Therapeutics has a consensus price target of $20.72, representing about 73.9% upside from its current price of $11.91.Amount of Analyst CoverageIntellia Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Intellia Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Intellia Therapeutics are expected to grow in the coming year, from ($3.21) to ($2.32) per share.Price to Book Value per Share RatioIntellia Therapeutics has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Intellia Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted33.36% of the float of Intellia Therapeutics has been sold short.Short Interest Ratio / Days to CoverIntellia Therapeutics has a short interest ratio ("days to cover") of 9.47.Change versus previous monthShort interest in Intellia Therapeutics has recently decreased by 3.37%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntellia Therapeutics does not currently pay a dividend.Dividend GrowthIntellia Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.69 News SentimentIntellia Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Intellia Therapeutics this week, compared to 7 articles on an average week.Search Interest24 people have searched for NTLA on MarketBeat in the last 30 days. This is an increase of 26% compared to the previous 30 days.MarketBeat Follows10 people have added Intellia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Intellia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,170.00 in company stock.Percentage Held by Insiders3.50% of the stock of Intellia Therapeutics is held by insiders.Percentage Held by Institutions88.77% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Intellia Therapeutics' insider trading history. Receive NTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NTLA Stock News HeadlinesIntellia Therapeutics, Inc. Announces Appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, Effective October 26, 2026October 13 at 12:07 PM | marketscreener.comMIntellia Therapeutics Names New CMO To Oversee Clinical And Regulatory FunctionsOctober 13 at 12:07 PM | rttnews.comThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up to $1,127 a month from a little-known 15 dollar fund built around it. This fund turns gold's price swings into cash, paid out every single Friday. | Investors Alley (Ad)Intellia Therapeutics Appoints Jing L. Marantz, M.D.October 13 at 7:30 AM | globenewswire.comIntellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by BarclaysOctober 8, 2026 | americanbankingnews.comIntellia Therapeutics (NASDAQ:NTLA) Raised to "Strong Sell" at BarclaysOctober 8, 2026 | americanbankingnews.comIntellia Therapeutics Inc (NTLA)October 7, 2026 | in.investing.comIntellia Therapeutics (NASDAQ:NTLA) Stock: Insider Michael Dube Sells 1,864 SharesOctober 7, 2026 | insidertrades.comSee More Headlines NTLA Stock Analysis - Frequently Asked Questions How have NTLA shares performed this year? Intellia Therapeutics' stock was trading at $8.99 on January 1st, 2026. Since then, NTLA stock has increased by 32.5% and is now trading at $11.91. How were Intellia Therapeutics' earnings last quarter? Intellia Therapeutics, Inc. (NASDAQ:NTLA) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.00. The firm's revenue for the quarter was down 46.4% on a year-over-year basis. Read the conference call transcript. When did Intellia Therapeutics IPO? Intellia Therapeutics (NTLA) raised $102 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Intellia Therapeutics' major shareholders? Intellia Therapeutics' top institutional investors include Versant Capital Management Inc and Farther Finance Advisors LLC. Insiders that own company stock include John M Leonard, Edward J Dulac III, William J Chase, James Basta, Birgit C Schultes, Eliana Clark, Michael P Dube, David Lebwohl, Laura Sepp-Lorenzino, Glenn Goddard and Jesse Goodman. View institutional ownership trends. How do I buy shares of Intellia Therapeutics? Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Intellia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intellia Therapeutics investors own include CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU) and Block (XYZ). Company Calendar Last Earnings8/06/2026Today10/14/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 NTLA's financial health is in the Green zone, according to TradeSmith. NTLA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NTLA CIK1652130 Webwww.intelliatx.com Phone(857) 285-6200FaxN/AEmployees377Year Founded2014Price Target and Rating Average Price Target for Intellia Therapeutics$20.72 High Price Target$49.00 Low Price Target$5.00 Potential Upside/Downside+73.9%Consensus RatingHold Rating Score (0-4)2.26 Research Coverage23 Analysts Profitability EPS (Trailing Twelve Months)($3.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$412.69 million Net Margins-672.16% Pretax Margin-672.16% Return on Equity-57.79% Return on Assets-47.29% Debt Debt-to-Equity RatioN/A Current Ratio6.65 Quick Ratio6.65 Sales & Book Value Annual Sales$67.67 million Price / Sales24.66 Cash FlowN/A Price / Cash FlowN/A Book Value$5.80 per share Price / Book2.05Miscellaneous Outstanding Shares140,130,000Free Float135,223,000Market Cap$1.67 billion OptionableOptionable Beta1.80 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:NTLA) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThis AI fund posted a 34 percent annualized payout last monthOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
